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Abstract. Lung cancer is one of the most common cancers 
worldwide. Arsenic trioxide (ATO) has been approved by the 
US Food and Drug Administration for the treatment of acute 
promyelocytic leukemia. Nonetheless preliminary data have 
suggested potential activity of ATO in solid tumors including 
lung cancer. This study aimed to examine the underlying 
mechanisms of ATO in the treatment of lung adenocarcinoma. 
Using a panel of 7 lung adenocarcinoma cell lines, the effects 
of ATO treatment on cell viability, expression of E2F1 and 
its downstream targets, phosphatidylserine externalization, 
mitochondrial membrane depolarization and alteration of 
apoptotic/anti-apoptotic factors were studied. Tumor growth 
inhibition in vivo was investigated using a nude mouse xeno-
graft model. ATO decreased cell viability with clinically 
achievable concentrations (8 µM) in all cell lines investigated. 
This was accompanied by reduced expression of E2F1, 
cyclin A2, skp2, c-myc, thymidine kinase and ribonucleotide 
reductase M1, while p-c-Jun was upregulated. Cell viability 
was significantly decreased with E2F1 knockdown. Treatment 
with ATO resulted in phosphatidylserine externalization in 
H23 cells and mitochondrial membrane depolarization in all 
cell lines, associated with truncation of Bid, downregulation 
of Bcl-2, upregulation of Bax and Bak, caspase-9 and -3 acti-
vation and PARP cleavage. Using the H358 xenograft model, 
the tumor growth was suppressed in the ATO treatment group 
during 8 days of treatment, associated with downregulation of 
E2F1 and upregulation of truncated Bid and cleaved caspase-3. 
In conclusion, ATO has potent in vitro and in vivo activity in 
lung adenocarcinoma, partially mediated through E2F1 down-
regulation and apoptosis.
Introduction
Based on the updated GLOBOCAN project of the World 
Health Organization in 2012, breast, prostate and lung remain 
the three most common global cancers (http://globocan.iarc.
fr/). The incidence and mortality rates of lung cancer have 
increased from 12.7 to 16.7% and 18.2 to 23.2% of all cancers 
respectively since 2008. Lung cancer is histologically classified 
as non-small cell (NSCLC) or small cell carcinoma (SCLC), 
and is associated with distinct treatment implications. The 
majority (85%) of lung cancer cases are NSCLC, comprised 
mostly of adenocarcinoma. Notably, tobacco smoking, pre-
existing lung disease, diet, occupational exposure, exposure 
to estrogen, and genetic predisposition are the major causes of 
lung cancer (1).
Systemic chemotherapy remains the cornerstone treat-
ment for advanced or metastatic NSCLC. First-line platinum 
doublets with newer agents (docetaxel, gemcitabine, paclitaxel, 
pemetrexed or vinorelbine) and salvage monotherapy with 
docetaxel or pemetrexed have conferred only a modest survival 
benefit with 5-year overall survival <5% (2,3). Emerging 
molecularly-targeted therapy against epidermal growth factor 
receptor or anaplastic lymphoma kinase has provided a supe-
rior treatment option to systemic chemotherapy in patients 
with NSCLC driven by actionable targets. Nonetheless devel-
opment of acquired drug resistance ~1 year following targeted 
therapy is almost inevitable (4). Thus novel effective treatment 
for NSCLC is urgently needed.
Arsenic trioxide (ATO), which is now a standard treat-
ment for acute promyelocytic leukemia, has demonstrated 
promising activity in solid tumors including lung cancer 
(5-8). Nonetheless the exact mechanisms of action of ATO 
in NSCLC have not been fully elucidated. We have recently 
reported the role of ATO-induced suppression of thymidylate 
synthase (TYMS) in 4 lung adenocarcinoma cell lines with 
basal expression (9), while ATO might have other effects in cell 
lines not expressing TYMS. The role of E2F1 is still not fully 
elucidated, therefore, a panel of 7 lung adenocarcinoma cell 
lines with basal E2F1 expression was studied. E2F1 is a tran-
scription factor that controls cell fate including apoptosis (10) 
and DNA synthesis (11). Depending on specific cancer types, 
the E2F1 gene can serve as an oncogene (12) with a prognostic 
role (13) or a tumor suppressor gene (14). This study aimed to 
investigate the action of ATO in lung adenocarcinoma, with an 
emphasis on E2F1-mediated pathways and apoptosis.
Materials and methods
Cell lines and reagents. A panel of 7 lung adenocarcinoma cell 
lines was obtained from the American Type Culture Collection 
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(Manassas, VA, USA). Cells were incubated in RPMI-1640 
culture medium (Gibco®, Life Technologies, Carlsbad, CΑ, 
USA) containing 10% fetal bovine serum (FBS) (Gibco) in 
a humidified atmosphere at 37˚C with 5% CO2. ATO was 
purchased from Sigma-Aldrich (St. Louis, MO, USA).
Assay of cell viability. Cell viability following ATO treatment 
was measured using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-
tetrazolium bromide (MTT) assay as previously described (9).
Western blot analysis of cell lysates. Sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) and western 
blot analysis were carried out as described (15). Primary 
antibodies were purchased from Cell Signaling Technology 
(Danvers, MA, USA). β-actin (Sigma-Aldrich) was used as a 
house-keeping protein.
E2F1 siRNA knockdown. Cells were cultured for 6 h with a 
mixture of transfection reagent and control (sc-37007) or E2F1 
(sc-29297) siRNA (Santa Cruz Biotechnology, Inc., Santa 
Cruz, CA, USA) in RPMI-1640 medium. The transfected cells 
were maintained in 1% FBS-containing medium for 2 days. 
Cell viability and E2F1 expression were assessed by MTT 
assay and western blot analysis, respectively (9).
Phycoerythrin (PE)-conjugated Annexin V and 7-(aminoacti-
nomycin D) AAD staining. Phosphatidylserine externalization 
(PS) (loss of membrane asymmetry) was examined using the 
PE-conjugated Annexin V and 7-AAD staining method as 
previously described (15).
Measurement of mitochondrial membrane potential by JC-1 
staining. The fluorescent dye JC-1 was employed for the 
determination of mitochondrial transmembrane potential. 
ATO-treated cells were harvested and re-suspended for 15 min 
at 37˚C in darkness with RPMI medium containing 2.5 µg/
ml JC-1 (Sigma-Aldrich). Flow analysis was performed and 
signals were detected by FL-1 (525 nm) and FL-2 (575 nm) 
channels (Beckman FC500).
Tumor growth inhibition in vivo. Tumor xenograft was estab-
lished by subcutaneous injection of 10 million H358 cells in 
PBS into the back of nude mice (female, 4-week-old, 10-12 g, 
BALB/cAnN-nu, Charles River Laboratories, Wilmington, 
MA, USA). Tumors were allowed to grow for 5 days before 
mice were randomised to two groups. ATO at 5 mg/kg (n=8) 
or PBS as control (n=7), was daily administered intraperito-
neally. Tumor growth was measured using standard calipers 
and body weight of mice was recorded on alternate days. 
Tumor volume (V) was calculated [V = (length x width x 
width)/2] (16). Mice were sacrificed following completion of 
ATO treatment. Tumor xenografts were collected and homog-
enized to obtain protein lysates for western blot analysis. The 
in vivo study was approved by the Committee on the Use of 
Live Animals in Teaching and Research (CULATR) of the 
University of Hong Kong (CULATR reference no. 2510-11).
Statistical analysis. Data from three individual experiments 
are shown as mean ± standard deviation (SD). Comparison 
between groups was performed using Student's two-tailed 
t-test by Prism (GraphPad Software, La Jolla, CA, USA). A 
p-value <0.05 was considered statistically significant.
Results
In vitro activity of ATO in lung adenocarcinoma. Incubation 
with ATO for 48 h reduced cell viability in different lung 
adenocarcinoma cell lines, with IC50 values ranging from 
1.8 to 16.5 µM (H23, H358, HCC827, H1650, H1975, HCC2935 
and HCC4006 cells: 1.8, 16.1, 2.0, 3.8, 2.6, 12.1 and 9.0 µM, 
respectively). After 72 h of ATO treatment, IC50 values were 
further decreased (H23, H358, HCC827, H1650, H1975, 
HCC2935 and HCC4006 cells: 0.5, 7.4, 0.08, 4.0, 1.5, 5.7 and 
4.0 µM, respectively).
Downregulation of E2F1 and alteration of related downstream 
proteins. ATO reduced expression of E2F1 (Fig. 1A) in a dose-
dependent manner, thus downstream targets of E2F1 were also 
investigated. Expression of cyclin A2 (Fig. 1B) was consistently 
downregulated by ATO in all cell lines. ATO also decreased 
the expression of skp2 (all cell lines except HCC4006 cells) 
(Fig. 1C), c-myc (H23 and H1975 cells) (Fig. 1D), thymidine 
kinase (TK) (H358, H1650, HCC2935 and HCC4006 cells) 
(Fig. 1E) and ribonucleotide reductase M1 (RRM1) (all cell 
lines except HCC827 and H1975 cells) (Fig. 1F). Nevertheless 
ATO upregulated p-c-Jun in H23, H358, HCC827 and H1975 
cells (Fig. 1G). Representative western blots are shown in Fig. 1.
E2F1 downregulation reduced cell viability. The role of E2F1 
in lung adenocarcinoma was studied using siRNA knockdown. 
With E2F1 protein expression decreased by 50-80% compared 
with control siRNA treatment, cell viability was significantly 
decreased by 60-88% (Fig. 2).
Phosphatidylserine (PS) externalization and mitochondrial 
membrane depolarization induced by ATO. ATO caused PS 
externalization in H23 cells only (Fig. 3A). Nonetheless ATO 
aggravated mitochondrial membrane depolarization in all cell 
lines in a dose-dependent manner (Fig. 3B).
Alteration of apoptosis-related factors by ATO. Truncated BID 
was detected in H358, H1650 and HCC2935 cells (Fig. 4A) 
following treatment with ATO. In contrast, there was a dose-
dependent downregulation of Bcl-2 in all cell lines (Fig. 4B), 
and upregulation of Bax in H23 cells (Fig. 4C). There was 
also a dose-dependent increase in expression of Bak in all 
cell lines (Fig. 4D). Expression of cleaved caspase-9 was 
elevated in H827 cells (Fig. 4E). On the other hand, cleaved 
caspase-3 (CC3) was activated in H23, HCC827, H1975 and 
HCC4006 cells, but unaltered in H1650 and downregulated in 
HCC2935 cells. The expression of CC3 in H358 cells was first 
elevated when exposed to 5 µM ATO, then suppressed with 
10 µM ATO (Fig. 4F). Caspase-3 expression was decreased 
in H358 and H2935 cells upon treatment with ATO (Fig. 4G). 
The expression of cleaved PARP was also augmented in H23, 
H358 and H1975 cells (Fig. 4H). Representative western blots 
are shown in Fig. 4.
In vivo effect of ATO on tumor xenografts. Tumor growth was 
observed by day 5 following implantation of H358 cells. Mice 
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Figure 1. Downregulation of E2F1 and its downstream targets by ATO in different lung adenocarcinoma cell lines. ATO reduced expression of E2F1 (A), 
cyclin A2 (B), skp2 (C), c-myc (D), TK (E) and RRM1 (F), while expression of p-c-Jun (G) was increased. β-actin was used as an internal control. A 
representative western blot is shown for each, except for those with undetectable basal expression. Statistical significance (*p<0.05, **p<0.01, ***p<0.001) is 
indicated for comparison with control.
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Figure 3. PE-conjugated Annexin V/7-AAD staining and JC-1 staining of ATO-treated lung adenocarcinoma cells. (A) Phosphatidylserine externalization was 
observed in ATO-treated H23 cells as evidenced by an increased percentage of cells stained with Annexin V. (B) Cells with depolarized mitochondrial mem-
brane were elevated in all cell lines after incubation with ATO. Statistical significance (*p<0.05, **p<0.01, ***p<0.001) is indicated for comparison with control.
Figure 2. Effect of E2F1 knockdown on cell viability in cells treated with E2F1-targeted siRNA. With E2F1 knockdown, cell viability was significantly 
decreased in different cell lines. Statistical significance (*p<0.05, **p<0.01, ***p<0.001) is indicated for comparison with control.
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were then randomly assigned to two treatment groups with no 
significant difference in baseline tumor volume. Tumor growth 
was significantly suppressed in the ATO treatment group 
compared with controls during 8 days of treatment (Fig. 5A). 
As the tumor size had reached the humane endpoint (a width 
of 17 mm) in control group, mice were sacrificed after 8 days 
of treatment. The relative tumor volume in the ATO treatment 
arm was 32% that of the control group at the end of treatment 
(p=0.0072). No obvious toxic effect due to ATO treatment was 
noted and all the mice were alive following 8 days of treatment. 
Figure 4. Alteration of apoptotic factors in lung adenocarcinoma cell lines by ATO. Truncation of BID was observed in H358, H1650 and HCC2935 cells (A). 
Bcl-2 was downregulated in all cell lines (B). Upregulated Bax was found in H23 cells (C). 
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Figure 4. Continued. The expression of Bak was elevated in all cell lines (D). Caspase-9 was activated in HCC827 cells (E). Cleaved caspase-3 (CC3) was 
upregulated by ATO in H23, H358, HCC827, H1975 and HCC4006 cells. The expression of CC3 was unchanged in H1650 cells. CC3 expression was decreased 
in H358 and HCC2935 cells with 10 µM ATO (F).
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The body weight of mice in the ATO treatment group and 
control group was similar during treatment. Based on western 
blotting, E2F1 protein was downregulated and truncated BID 
and cleaved caspase-3 were upregulated with ATO treatment 
(Fig. 5B). Histological examination (H&E staining) of tumor 
sections revealed prominent apoptosis (formation of apoptosis 
Figure 4. Continued.  Caspase-3 was downregulated in H358 and HCC2935 cells (G). Cleavage of PARP was observed in H23, H358 and H1975 cells (H). A 
representative western blot was shown except for those with undetectable basal expression. β-actin was used as a housekeeping protein. Statistical significance 
(*p<0.05, **p<0.01, ***p<0.001) is indicated for comparison with control.
Figure 5. Tumor growth in vivo was inhibited by ATO in H358 xenograft model. ATO treatment was associated with (A) suppression of tumor growth and 
(B) downregulation of E2F1 as well as upregulation of truncated BID and CC3 expression in the ATO treatment group compared with control group in 
H358 xenograft model. Statistical significance (*p<0.05, **p<0.01, ***p<0.001) was indicated for comparison with control. (C) Tumor sections were examined 
histologically with H&E staining, showing prominent apoptosis (examples indicated by arrows) among the ATO treatment group. Representative histological 
sections of tumor xenografts are shown (x200). (D) Immunostaining for CC3 showed nuclear localization in ATO-treated xenografts, while a lack of com-
partmentalization was evident in the control.
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bodies) with ATO treatment (Fig. 5C). Immunohistochemical 
staining demonstrated nuclear localization of cleaved 
caspase-3 in the ATO treatment group (Fig. 5D).
Discussion
In our cell line and xenograft models, ATO has demonstrated 
anti-proliferative and cytotoxic activity in lung adenocarci-
noma at least partially mediated via downregulation of E2F1 
and apoptosis. The concentrations of ATO corresponding 
to the in vitro IC50 values were within a clinically reachable 
plasma level (8.3 µM) (17). The regulatory role of E2F1 in 
cellular proliferation in lung adenocarcinoma cell lines was 
confirmed using E2F1 siRNA knockdown experiment.
Pi Shuang is notoriously poisonous and has been para-
doxically used in traditional Chinese medicine to treat 
various conditions, including cancers. The active ingredient 
of Pi Shuang is now known to be arsenic trioxide (As2O3 or 
ATO). ATO has been shown to induce apoptosis (at 0.5-2 µM) 
and promote cellular differentiation (at 0.1-0.5 µM) in acute 
promyelocytic leukemia (APL) cells (18). Its mechanisms of 
action in leukemia have been extensively investigated in the 
past decade, and involve alteration or activation of Bcl-2, 
cytochrome c, caspase-9, -3 and reactive oxygen species (19), 
p73, XIAP, cIAP2, Bcl-xL and survivin (20), DNA mutation 
and apoptosis (21), tubulin assembly disarrangement and 
microtubule depolymerization (22), survivin and telomerase 
(7). An intravenous formulation of ATO has received approval 
from the US Food and Drug Administration in the treatment 
of APL. In recent years, our institution has developed an 
oral liquid form of ATO that is more convenient for clinical 
use with a better safety profile (5). The role of ATO in the 
treatment of NSCLC has been less well-defined, though some 
preclinical data have suggested potential activity. We therefore 
aimed to further investigate the activity and mechanisms of 
action of ATO in preclinical models of lung adenocarcinoma.
The role of E2F1 in cancer appears to be a double-edged 
sword, with oncogenic or tumor suppressive properties, 
depending on the specific cancer type. In human breast cancer: 
E2F1 mRNA expression was lower with more advanced tumor 
stage in malignant breast tissue (23), nonetheless E2F1 was 
shown to promote proliferation in breast cancer cells (24). In 
NSCLC, E2F1 was reported to be oncogenic (12) and associ-
ated with an adverse prognosis (13) that is also observed in 
thyroid (25), liver (26) and pancreatic (27) cancers.
E2F1 consists of a cyclin A binding domain, DNA binding 
domain, pocket protein binding domain, nuclear export signal 
and nuclear localization signal (11). It is a transcription factor 
that controls apoptosis, cell cycle, senescence and tumor 
growth (10), as well as DNA damage, repair, synthesis and 
replication (11). The E2F1 pathway is frequently deregulated 
in cancers. As a consequence, amplification of cyclin A2 (28), 
c-myc (29), thymidylate synthase (TYMS) (30) and skp2 (31) 
is commonly found in various tumors, serving as important 
cell cycle regulators that are essential for cell proliferation. 
Thymidine kinase (TK) overexpression is associated with a 
higher incidence of clinical disease recurrence and mortality 
in breast cancer (32), while a lower level of expression of 
ribonucleotide reductase M1 (RRM1) predicts a longer time 
to progression in lung cancer with chemotherapy treatment 
(33). Activation of c-Jun is correlated with CHOP upregulation 
and induction of apoptosis by AW00178 in human H1299 lung 
carcinoma cells (34) and apoptosis activation by 6-(7-nitro-
2,1,3-benzoxadiazol-4-ylthio)hexanol in multidrug-resistant 
small cell lung cancer H69AR cells (35). These important 
molecular signals are ultimately controlled by E2F1. In this 
study, ATO has been shown to suppress E2F1 expression with 
alteration of its downstream targets. Notably TYMS (9), TK 
and RRM1 were downregulated, leading to inhibition of DNA 
synthesis. In addition, decreased expression of other prolifera-
tion factors (cyclin A2, c-myc, skp2) may also have contributed 
to the observed antiproliferative effect of ATO.
While E2F1 has been reported as an oncogene (12), its 
functional role in lung adenocarcinoma was demonstrated by 
specific E2F1 siRNA knockdown in our cell line model. Upon 
E2F1 knockdown by 50-80%, cell viability was significantly 
reduced by 60-88%, in support of its critical role in cell survival. 
The same phenomenon was recently reported in other lung 
cancer cell lines (36), nonetheless neither downstream targets 
of E2F1 nor other possible mechanisms were studied. In our 
study, E2F1 and its downstream targets were downregulated 
with ATO treatment, while the pro-apoptotic factor p-c-Jun 
was upregulated. As an executioner of apoptosis, expression of 
cleaved caspase-3 (CC3) after E2F1 knockdown was investi-
gated. By simply knocking down E2F1, expression of CC3 was 
increased in HCC2935 cells only (data not shown), suggesting 
that E2F1 is mainly responsible for cell proliferation rather 
than apoptosis.
Although the induction of cell death by ATO has been 
investigated extensively in different cancer models, only a few 
reports have shown ATO-induced PS externalization (37-41). 
To our knowledge, this is the first report of PS externalization 
in an ATO-treated lung cancer cell line (H23). Nonetheless 
flow analysis did reveal that more cells became susceptible 
to mitochondrial membrane depolarization across different 
cell lines in our model with treatment of increasing ATO 
concentration, similar to previous reports in both lung cancer 
(8,42,43) and other cancer cell lines (44-46).
Theoretically, truncation of BID can increase the expres-
sion of Bax and Bak. Together with reduction in the expression 
of Bcl-2, an anti-apoptotic factor, truncated BID can direct the 
activation of caspase-9 and -3. The activation of caspase-3 may 
then cleave PARP leading to apoptosis. Thus the key apoptotic 
factors related to mitochondrial pathway were investigated in 
our lung adenocarcinoma cell line model with ATO treatment.
The expression of Bcl-2 was frequently inhibited by ATO 
in other lung cancer cell lines (8,47,48). In accordance with 
previous reports, we have demonstrated downregulation of Bcl-2 
expression in our panel of ATO-treated lung adenocarcinoma 
cell lines. Upregulation of Bax was induced by ATO in H23 
cells, while a similar phenomenon was only reported in small 
cell lung carcinoma (49). Nonetheless expression of Bak was 
elevated across different lung adenocarcinoma cell lines with 
ATO treatment. This is the first report to date of BID truncation 
and Bak upregulation in ATO-treated lung cancer cell lines.
Although there are reports of cleaved caspase-9 upregula-
tion by ATO in other cancer cell lines (50,51), our similar 
observation in HCC827 cells is the first report in a lung cancer 
model. Caspase-3 activation was shown in ATO-treated A549 
cells (52), Calu-6 cells (8) and SCLC cell lines (49). This study 
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has reinforced these findings in a panel of lung adenocarcinoma 
cell lines. Interestingly, the expression of CC3 in H358 cells was 
first increased when exposed to 5 µM ATO and then decreased 
with 10 µM ATO, whereas, CC3 expression decreased in a dose-
dependent manner in HCC2935 cells when incubated with ATO. 
A similar observation was reported with prolonged incubation 
of ATO in lymphocytic leukemia cells (53). This paradoxical 
result was due to the direct suppression of caspase-3 expression 
by ATO in H358 and HCC2935 cells, and has been previously 
reported (53). ATO-induced cleavage of PARP has been reported 
in the H1355 NSCLC cell line (54) and in SCLC cell lines (49). 
We have provided further evidence of PARP cleavage in lung 
adenocarcinoma cell lines with ATO treatment.
Apart from promising in vitro activity in our lung adeno-
carcinoma model, the in vivo effect of ATO was confirmed 
using a nude mouse xenograft model. E2F1 downregulation 
was observed in tumor xenografts in keeping with the antip-
roliferative effect of ATO. Moreover, formation of apoptotic 
bodies and upregulation of truncated Bid and CC3 were also 
observed in treated tumor xenografts. Translocation of CC3 
from the cytoplasm to the nucleus was shown by IHC staining. 
Pro-caspase-3 is located predominantly in the cytoplasm 
of cells. Caspase-3 is activated by upstream caspases and 
its active form (CC3) is then translocated into the nucleus. 
The substrates in the nucleus, e.g., PARP, are then cleaved. 
Eventually, chromatin condensation, DNA fragmentation and 
nuclear disruption occur and cells are directed to apoptosis 
(55). Our findings have provided evidence that apoptosis is 
induced by ATO in a lung adenocarcinoma xenograft model.
In conclusion, the anticancer effect of ATO was demon-
strated through antiproliferation (E2F1 downregulation) and 
cell death (apoptosis) in both in vitro and in vivo lung adeno-
carcinoma models. Our novel finding of E2F1 suppression by 
ATO provides an additional mechanism to explain the activity 
of ATO in lung adenocarcinoma. Future potential clinical 
applications of ATO in lung adenocarcinoma treatment should 
be explored.
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